Experience

Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by NeoGenomics, Inc. of 4,400,000 shares of its common stock and $175 million…

Davis Polk advised the dealer manager in connection with the private offer by Envision Healthcare Corporation to exchange approximately $106 million of its new first-lien senior secured…

Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered common stock and pre-funded warrants offering by Aeglea, including the full exercise…

Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.250% senior notes due 2030…

Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus BioSciences, Inc. of $200 million aggregate principal amount of its…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc. of $287.5 million aggregate principal amount of its 2.25%…

Davis Polk advised the sole book-running manager in connection with the SEC-registered offering by Nevro Corp. of $189.75 million aggregate principal amount of its 2.75% convertible…

Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of $1.5 billion aggregate principal amount of 2.400% senior notes due…